Abstract
This study represents the first report of gene therapy for anaplastic thyroid carcinoma, one of the most aggressive solid tumors in humans. Two patients with end-stage anaplastic thyroid carcinoma were treated by direct intratumor injection of retroviral vector producer cells followed by ganciclovir. The retroviral vector carried the human IL-2 gene and the suicide gene thymidine kinase of herpes simplex virus type 1. Treatment was safe and associated with only mild adverse events. Transduction of tumor cells and production of T helper type 1 cytokines was demonstrated in tumor biopsies. Gene therapy led also to a marked increase in T helper type 1 cytokine expression in peripheral blood mononuclear cells. Radiological evaluation of injected tumor masses demonstrated local tumor necrosis. Copyright © 2005 by The Endocrine Society.
Cite
CITATION STYLE
Barzon, L., Pacenti, M., Taccaliti, A., Franchin, E., Bruglia, M., Boscaro, M., & Palù, G. (2005). Brief report: A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 90(5), 2831–2834. https://doi.org/10.1210/jc.2004-2139
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.